ClinicalTrials.gg
WithdrawnNCT00505258Updated Feb 20, 2013

Ceftobiprole in the Treatment of Hospitalized Patients With Staphylococcus Aureus Bacteremia

A Phase 2 interventional study of ceftobiprole medocaril in Bacteremia, sponsored by Basilea Pharmaceutica. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-02-20.

Sponsored by Basilea Pharmaceutica · Phase 2, Interventional, and Treatment

Why this study was withdrawn
The study was withdrawn due to lack of an appropriate patient population.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the safety and efficacy of ceftobiprole versus a comparator in hospitalized patients with bacteremia.

Read the detailed description

Ceftobiprole medocaril is a cephalosporin antibiotic with anti-MRSA (Methicillin-Resistant Staphylococcus aureus) activity. Ceftobiprole medocaril in not approved for the treatment of bacterial blood stream infections. S. aureus is a major human pathogen. It causes a wide range of serious infections, including skin and skin structure infections, infections of vascular devices and catheters, and infections of the heart and lungs, bones and joints, and deep tissues. Particularly challenging and difficult to treat are blood-borne infections (bacteremia). Bacteremic infections are prone to relapse and they are often complicated by metastatic seeding of sites throughout the body. MRSA strains are increasing in prevalence, incidence, and virulence. Moreover, the frequency of patients presenting with persistent MRSA bacteremia appears to be rising. The objective of the open label trial is to compare the effectiveness and safety of ceftobiprole versus a comparator in patients with MRSA and MSSA (methicillin-susceptible Staphylococcus aureus) in bacteremic patients. Patients who meet inclusion and exclusion criteria and consent to participate in the study will be randomly assigned to either ceftobiprole or comparator. The primary end point is time to bloodstream clearance of MRSA and MSSA in patients. Patients will be randomized to either ceftobiprole or comparator for 7 days.

02

Conditions studied

  • Bacteremia

Keywords

  • Bacteremia
  • Bloodstream infection
  • Staphylococcus aureus
  • Staphylococcal Infections
  • MRSA
  • MSSA
03

In context

Bacteremia

298 studies on the registry are indexed under Bacteremia; 51 are open to participants now.

Browse Bacteremia studies →

Lead sponsor

Basilea Pharmaceutica is the lead sponsor of 60 studies on the registry; 7 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 15 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospitalized patients with signs and symptoms suggestive of systemic staphylococcal infection as defined in the protocol
  • Female patients must be (for at least 1 year), surgically sterile or practicing an effective method of , male partner sterilization or, at the discretion of the investigator, abstinence, before entry and throughout the study and have a negative urine pregnancy test (confirmed with a negative serum pregnancy test) at screening.

Exclusion criteria

Exclusion Criteria:

  • Female patients who are pregnant or lactating
  • Known or suspected to beta-lactam antibiotics or any other study medications
  • Receipt of vancomycin or other antistaphylococcal drug for > 2 calendar days prior to initiation of study drug
  • Diagnosis of a catheter-related GPC-cl bacteremia at the time of study enrollment
  • Clinical findings of left-sided endocarditis prior to enrollment or any time during study participation
  • Requirement for surgery during the seven days of study therapy administration with the exception of surgery required to manage a complication of S. aureus bacteremia
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. To determine the effect of ceftobiprole on the time to bloodstream clearance of methicillin-resistant Staphylococcus aureus and methicillin-susceptible Staphylococcus aureus (MSSA) in treated bacteremic patients.

Secondary outcomes

  1. To determine the effect of ceftobiprole versus comparator on the time to bloodstream clearance of MRSA and MSSA, respectively and bloodstream clearance of MRSA compared to MSSA in bacteremic patients.

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 20, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00505258
Responsible party
Sponsor
First posted
Jul 23, 2007
Completion
Apr 2009 (estimated)
Last update
Feb 20, 2013

Study contacts

Ortho-McNeil Janssen Scientific Affairs, LLC Clinical Trial
study director · Ortho-McNeil Janssen Scientific Affairs, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ceftobiprole medocaril

Start the discussion